Reply to F. Dayyani et al

Affiliation

• ¹ Sarah Watson, MD, PhD, Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France, INSERM U830, Cancer, Heterogeneity, Instability and Plasticity (CHIP), Equipe labellisée par la Ligue Nationale contre le Cancer, Institut Curie, PSL Research University, Paris, France; Joanna Cyrta, MD, PhD, Department of Pathology, Institut Curie, PSL Research University, Paris, France.